Fritextsökning
Artiklar per år
Innehållstyper
-
Över 200 miljoner kronor till hälsoforskning
Hjärnsjukdomar, cancer, fetma och hjärtkärlsjukdomar. Det är några av de behandlingsområden som nu får forskningsstöd från Vinnova inom det nya programmet "Innovationer för framtidens hälsa".
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Swedish multi competent machine soon launched
The Swedish company Biosensor will launch new equipment able to detect twelve different narcotics and explosives simultaneously.
-
New map of eye proteins
A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.
-
Vitrolife wants to acquire Medicult
The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.
-
Prenatal testing breakthrough
For the first time specific gene expression information from fetal cells isolated from maternal blood samples is available.
-
Danish discovery could help cardiac patients
The Danish researchers have developed a component that could make live easier forpatients with heart failure.
-
Biogaia's advance goes on
In December Biogaia reached China and North America. Now, the Swedish probiotic company has entered the Mexican market.
-
New faces in Pronova Biopharma team
The Norwegian company Pronova Biopharma has recently changed the management team structure.
-
New firm based on SLU research
Four researchers at the Swedish University of Agricultural Sciences, SLU, has recently founded a new nanotech company.
-
A platform for dialogue
As a step towards connecting the life science industry in Denmark, Biologue was founded three years ago with 10 member companies. Today, the network has 40 members and a very busy event calender.